Published in:
01-06-2015 | Original Article
Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial
Authors:
Eun Hye Kim, Yong Chan Lee, Young Woon Chang, Jong-Jae Park, Hoon Jai Chun, Hwoon-Yong Jung, Hyun-Soo Kim, Hyun Yong Jeong, Sang-Young Seol, Sok Won Han, Myung-Gyu Choi, Soo-Heon Park, Ok-Jae Lee, Jin Tae Jung, Dong Ho Lee, Hyun Chae Jung, Soo Teik Lee, Jae Gyu Kim, Sei Jin Youn, Hak Yang Kim, Sang Woo Lee
Published in:
Digestive Diseases and Sciences
|
Issue 6/2015
Login to get access
Abstract
Background
There has been no study on the efficacy of lafutidine for patients with reflux esophagitis in Korea.
Aim
To evaluate the efficacy of a new-generation histamine-2 receptor antagonist, lafutidine, in comparison with famotidine in patients with reflux esophagitis.
Methods
This was a randomized, double-blind, non-inferiority trial enrolling patients with erosive esophagitis. The efficacy and safety of 20 mg lafutidine (treatment group) were compared with those of 40 mg famotidine (control group) and 20 mg omeprazole (reference group). The primary endpoint was the complete healing rates of reflux esophagitis on endoscopy after 8 weeks of treatment. The non-inferiority margin was assumed to be −15 %.
Results
The healing rates of reflux esophagitis on endoscopy after 8 weeks of treatment were 70.14 % (101/144) in the lafutidine, 63.45 % (92/145) in the famotidine, and 85.71 % (126/147) in the omeprazole group. The difference in healing rates between the lafutidine and famotidine groups was 6.69 % (95 % confidence interval = [−4.14 to 17.52]). In addition, lafutidine was superior to famotidine in clinical improvement (53.73 % vs. 39.55 %, P = 0.0200).
Conclusions
Lafutidine was non-inferior to famotidine in healing of reflux esophagitis. Lafutidine, however, was superior to famotidine in terms of symptom relief of reflux esophagitis.